CABS Precision Medicine for oncology and immunology-2017-03-25

Event Information
Event Name: 
CABS Precision Medicine for oncology and immunology
Event Date: 
03/25/2017 - 1:30pm
Event Location: 
Genentech Building 31, 1531 Grandview Drive South San Francisco CA, 94080
Event Details
Event Type: 
Panel Discussions
Event Details: 

CABS, Saturday Afternoon, March 25, 2017

Topic: “Precision Medicine for oncology and immunology”
Date and Time: Saturday March 25, 2017 @ 2:00 pm - 4:00 pm
Genentech Building 31, 1531 Grandview Drive South San Francisco CA, 94080 (Note venue change with added capacity and earlier check-in & networking start time)

Free
Register at http://www.cabsweb.org/registration/2455518/Precision%20Medicine%20for%2...

Presentations:
1. Liquid biopsies in precision drug development by Shidong Jia, Founder and CEO of Predicine Holdings Ltd.
Cancer immunotherapy and targeted therapy offer great promise in precision oncology, where predictive biomarkers have been extensively investigated in various types of cancer patients. The talk will describe development and clinical application of an innovative, next generation sequencing based liquid biopsy test to support cancer immunotherapy clinical trials.

Speaker Bio
Dr. Shidong Jia is the Founder and CEO of Predicine Holdings Ltd, an international precision medicine organization that is committed to developing innovative diagnostics, therapeutics and big data in cancer and other serious diseases. The company operates in California, USA and Shanghai, China. Driven by a passion to improve personalized medicine, Dr. Jia has dedicated the past 21 years to basic, translational, and clinical cancer research. His previous work identified p110beta as novel drug target for PTEN-deficient prostate tumors (Jia S, et al. Nature, 2008), a finding that laid the foundation for the clinical development and testing of p110beta inhibitors in cancers. Most recently, his team at Predicine developed world’s first ctRNA and ctDNA combined liquid biopsy test for precision medicine in cancer. A former Scientist, principal investigator and prostate cancer disease area lead at Genentech, Dr. Jia spearheaded the biomarker strategies and drug & diagnostics co-developments efforts in support of clinical oncology pipeline at various stages (i.e., early stage research, late stage research, early clinical development, Phase I and Phase II clinical trials), culminated by the Lifecycle Investment Point (LIP) achievement of driving an investigative drug from global Phase II into Phase III pivotal clinical trial. Prior to joining Genentech, Dr. Jia was Laboratory Head for Oncology Drug Discovery at the Novartis Institutes for BioMedical Research in Cambridge, MA. Dr. Jia serves as the Editor-in-Chief of "Journal of Circulating Biomarkers”, Guest Associate Editor of "Frontiers in Oncology", and Members of National Cancer Institute Review Committees and the Italian Ministry of Health - Scientific Research and Health Innovation Review Committee. Dr. Jia is a BayHelix member and receipt of several awards, including the "Young Investigator Award" at the Fourth Asian Congress for Microcirculation in Indonesia and the "P.A.R.T. Investigatorship Award" at the Dana-Farber Cancer Institute, Harvard Medical School in Boston.

2. Towards an Assay of Global Immunocompetence by Holden Maecker, Director, Human Immune Monitoring Center, Stanford
A long-term goal of our laboratory is to define metrics of healthy immune function and the deviations that predict or define disease states. There are many facets of the immune system that can be measured, and few clinically accepted tests of immune function. However, we hypothesize that a comprehensive assessment of the proportions, phenotypes, and functions of specific immune cell subsets in blood should be helpful in defining these metrics. We have therefore defined for this purpose a mass cytometry assay using phorbol myristate acetate (PMA)+ionomycin stimulation of peripheral blood mononuclear cells (PBMC), with staining for approximately 40 cell-surface and intracellular proteins, including lineage markers, cytokines, and other functional markers. Mass cytometry, or CyTOF, is a version of flow cytometry that uses heavy metal ion labels in place of fluorochromes, with readout by time-of-flight mass spectrometry. The CyTOF platform allows for many more labeled antibodies to be used in combination, with much less spillover between detection channels, compared to conventional flow cytometry. In this talk, I will describe this methodology and how we are applying it currently to the monitoring of patients undergoing cancer immunotherapy. Our goal in these studies is to better tailor immunotherapies to specific patients, and to suggest approaches that might be useful to address those patients with suboptimal immune function.

Speaker Bio
Dr. Holden T. Maecker received his PhD from Stanford University, is currently Assoc. Prof. at Microbiology & Immunology department and Director of Human Immune Monitoring Center at Stanford. His research is in the area of T cell response signatures and their association with protection from chronic pathogens and cancer. His lab has published a number of papers on this topic, both alone and in collaboration with other groups, in systems such as CMV, HIV, tuberculosis, and cancer. The Human Immune Monitoring Center (HIMC) is a Stanford core service laboratory, which performs blood processing and standardized assays using flow cytometry, genomics, and immunoassay platforms. For the past five years, his lab has gained extensive experience with CyTOF mass cytometry. In addition to being PI on multiple NIH, industry, and foundation grants, Dr. Maecker serves as a core leader for several cooperative center grants and other large collaborative projects, in which he oversees the use of HIMC assays, including data analysis and interpretation.